21.11.2026

Metastatic Breast Cancer with Liver Metastases: Re-biopsy, NGS and Treatment Planning

Breast cancer liver metastases occur when breast cancer cells spread to the liver. It is not primary liver cancer. The treatment plan should therefore be based on the current biology of the breast cancer, the extent and pace of the disease, previous treatment, symptoms, liver function, overall health and the patient’s priorities—not on the liver location alone.

 

The original breast-tumour report may no longer provide every answer needed for a current decision. When it can be performed safely and the result could change treatment, a biopsy of an accessible metastatic site may confirm the diagnosis and reassess oestrogen receptor, progesterone receptor and HER2. Tissue or blood-based genomic testing may add information about selected treatment-relevant alterations, but no test can guarantee that a matched medicine will be suitable, available or effective.

 

Systemic treatment remains the foundation of care because it can reach cancer cells in the liver and elsewhere in the body. Liver surgery, thermal ablation, stereotactic radiotherapy or an arterial treatment may be discussed for a small, carefully selected group after multidisciplinary review. These procedures should not be presented as routine alternatives to systemic therapy or as a guaranteed cure.

 

This guide explains the decision pathway from diagnosis confirmation and re-biopsy to biomarker interpretation, subtype-specific treatment, liver-directed procedures, monitoring and international care planning in Türkiye. It is written for global English-speaking patients, including people travelling from the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand and countries across Africa where English is widely used in healthcare and international communication.

 

Patients with rapidly worsening jaundice, confusion, bleeding, severe or increasing abdominal swelling or pain, persistent vomiting, fever during treatment, breathlessness or sudden loss of strength should seek urgent medical assessment where they are. A records review or international journey must not delay emergency care.

 

What Breast Cancer Liver Metastases Mean

 

Breast cancer liver metastases are deposits of breast cancer cells that have travelled to the liver. They are not the same disease as a cancer that began in the liver. Under the microscope and in treatment planning, the cancer is still classified according to its breast origin.

 

The presence of a confirmed distant metastasis means that the breast cancer is metastatic, or stage IV. Liver involvement may be discovered when breast cancer is first diagnosed, known as de novo metastatic disease, or it may appear months or years after treatment for an earlier-stage cancer. It can occur alone, but it more often exists alongside disease in other locations such as bone, lung, lymph nodes, skin or brain.

 

This distinction matters because the treatment plan is not based only on the organ where a metastasis is found. The oncology team must consider the biological subtype of the breast cancer, all sites of disease, previous treatments, the pace of progression, symptoms, liver function, other health conditions and the patient’s priorities.

 

Some people have one or a small number of liver lesions, while others have extensive or multi-organ disease. Some cancers remain sensitive to endocrine or targeted treatment; others progress rapidly or cause organ dysfunction. These situations should not be managed as if they were identical.

 

Imaging may strongly suggest liver metastases, but imaging alone does not always prove that every liver lesion represents a breast cancer metastasis. Benign liver findings are common, and a new lesion can occasionally have another cause. A tissue biopsy may therefore be important when the diagnosis is uncertain or when confirming the current tumour biology could alter treatment.

 

What Treatment Is Trying to Achieve

 

For most patients with metastatic breast cancer, treatment is intended to control the disease, relieve or prevent symptoms, preserve organ function, maintain quality of life and extend life where possible. Current systemic treatments can produce meaningful and sometimes prolonged control, but no ethical medical team should promise a particular response or duration.

 

The goal should be stated clearly for the individual patient. It may include:

 

  • reducing the amount of cancer in the liver and elsewhere;
  • preventing liver-related complications;
  • relieving pain, nausea, fatigue or pressure symptoms;
  • controlling a small area that is progressing while other disease remains stable;
  • maintaining daily activity and independence;
  • finding a treatment that is effective without unacceptable toxicity;
  • creating time for a later treatment option or clinical trial; or
  • providing comfort-focused care when further anticancer treatment is unlikely to help.

The same scan appearance can lead to different plans in different patients. For example, a person with hormone-receptor-positive disease, stable liver function and no organ crisis may be treated very differently from a person with rapidly rising bilirubin, widespread progression and declining performance status. Likewise, a patient with one liver lesion after a long disease-free interval may be evaluated differently from a patient whose cancer is progressing simultaneously in the liver, lung and brain.

 

The plan should be revisited after progression, a new biopsy result, a change in organ function or a serious side effect.

 

Confirming the Disease, Mapping Its Extent and Assessing Urgency

 

Before choosing treatment, the oncology team should answer three broad questions:

 

  1. Is the diagnosis sufficiently confirmed?
  2. Where is the disease, and how active is it?
  3. Is there an urgent threat to liver or other organ function?

Confirming the diagnosis

 

The team reviews the original breast pathology, operative reports, receptor results, previous molecular tests and the clinical course. If liver lesions are new, the radiologist assesses whether their appearance is typical of metastases and whether additional imaging is needed. A contrast-enhanced CT scan, liver MRI or another appropriate study may help define the number, location and characteristics of lesions. Whole-body staging is also important because a liver-only plan should not be made without considering disease elsewhere.

 

A biopsy may be proposed if the metastatic diagnosis has not previously been confirmed, the liver appearance is atypical, a long interval has passed since the original breast cancer diagnosis, another primary cancer is possible, or the result could change treatment.

 

Establishing the current disease burden

 

Assessment may include:

 

  • CT of the chest, abdomen and pelvis;
  • liver MRI when better characterisation or planning of local treatment is needed;
  • bone imaging or PET-CT in an appropriate clinical setting;
  • brain MRI for neurological symptoms; in selected asymptomatic patients with HER2-positive or triple-negative disease, brain imaging may also be considered when finding central-nervous-system disease would change systemic treatment;
  • full blood count;
  • liver and kidney function tests;
  • calcium, electrolytes and other treatment-specific tests;
  • review of weight, nutrition, pain and daily activity; and
  • examination for complications such as fluid accumulation, obstruction or infection.

Tumour markers may sometimes support monitoring, but they cannot establish the diagnosis or determine progression by themselves. Results must be interpreted together with symptoms, examination and imaging.

 

Liver metastases are not automatically a visceral crisis

 

The liver is a visceral organ, but the presence of liver metastases does not by itself mean that a patient is in visceral crisis. This distinction is clinically important.

 

Visceral crisis refers to severe, rapidly evolving organ dysfunction or an imminent threat of organ failure caused by the cancer. It is not simply the existence of visceral metastases, a large lesion or an abnormal scan. In the Advanced Breast Cancer consensus, a liver visceral-crisis example is rapidly increasing bilirubin above 1.5 times the upper limit of normal in the absence of Gilbert syndrome or biliary obstruction. Other severe evidence of worsening organ function may also constitute a crisis. A blocked bile duct, infection, medicine-related injury and non-cancer liver disease must be considered because they may require different treatment.

 

When a true visceral crisis or an impending crisis is present, the team prioritises the fastest effective subtype-appropriate treatment with a realistic chance of reversing organ dysfunction. When liver function is stable and no crisis is present, endocrine-based or other biology-directed treatment may remain appropriate according to subtype, previous therapy and disease pace.

 

The term should therefore be used by the treating oncologist after a full clinical assessment, not inferred by a patient from the words “liver metastases” on a scan report.

 

When and Why a Metastatic-Site Biopsy May Be Recommended

 

At the first diagnosis of metastatic breast cancer, a biopsy of an accessible metastatic site is generally recommended when it is technically feasible and the result is likely to be useful. The purpose is not merely to repeat a test. A new sample may answer questions that the original breast specimen cannot.

 

Potential reasons include:

 

  • confirming that the lesion is metastatic breast cancer;
  • excluding a benign lesion or a second primary cancer;
  • reassessing oestrogen receptor, progesterone receptor and HER2;
  • evaluating HER2 expression with current pathology methods;
  • obtaining material for additional immunohistochemistry;
  • producing tissue for clinically relevant molecular testing;
  • investigating an unexpected pattern of progression; or
  • examining resistance after previous treatment.

A liver lesion may be a good biopsy target because it can provide current metastatic tissue. It is not automatically the safest or best target. A lymph node, soft-tissue lesion or another metastasis may offer the same clinical information with less risk. Bone tissue can be useful, but processing that requires decalcification may interfere with some receptor and molecular tests. The pathologist and interventional radiologist should be involved in choosing the biopsy target.

 

When a new biopsy may not be appropriate

 

A biopsy should not be presented as mandatory in every patient. It may be deferred when:

 

  • the procedure would carry disproportionate risk;
  • no lesion can be sampled safely;
  • the patient is medically unstable and treatment cannot reasonably wait;
  • adequate recent metastatic tissue already answers the relevant question;
  • the result would not change the proposed treatment;
  • the patient does not wish to undergo the procedure after informed discussion; or
  • the clinical team judges that another diagnostic strategy is more appropriate.

If a biopsy is not feasible, the team may use the original or a previous metastatic specimen, blood-based molecular testing, or a combination of available evidence. The limitations of each option should be explained.

 

How biopsy safety and site are decided

 

Image-guided core-needle biopsy is commonly used for liver lesions because it can provide tissue architecture and enough material for several laboratory tests. The exact approach depends on lesion size and location, nearby blood vessels and organs, the route available to the radiologist, and whether viable tumour can be reached.

 

Before the procedure, the clinical team may review:

 

  • platelet count and clotting tests;
  • medicines that affect bleeding;
  • liver function;
  • infection risk;
  • history of allergies and previous sedation;
  • cardiopulmonary stability;
  • the patient’s ability to cooperate and remain in the required position; and
  • whether the amount of tissue required is realistic.

Possible complications include pain, bleeding, infection and injury to nearby structures. Serious complications are uncommon in experienced hands but cannot be excluded. The interventional team should explain case-specific risks, preparation, aftercare and warning signs.

 

Biopsy planning should also preserve enough tissue for the required tests. The oncologist, pathologist and molecular laboratory should agree on which tests are needed so that a limited specimen is not exhausted by unnecessary studies. If NGS is planned, the laboratory may specify tumour content, number of cores, fixation conditions and whether DNA, RNA or both are required.

 

Reassessing ER, PR and HER2

 

Breast cancer can evolve over time and under treatment pressure. The oestrogen receptor, progesterone receptor and HER2 status in a metastasis may differ from the original breast tumour. This is often called receptor discordance or receptor conversion.

 

For that reason, a metastatic biopsy is commonly tested again for:

 

  • oestrogen receptor, or ER;
  • progesterone receptor, called PR or PgR; and
  • human epidermal growth factor receptor 2, or HER2.

These results help define the current treatment options. A cancer that remains hormone-receptor positive may be sensitive to endocrine-based treatment. HER2-positive disease may qualify for HER2-directed therapy. Triple-negative disease is defined by the absence of ER, PR and HER2 positivity and follows a different treatment pathway.

 

Discordance does not have one automatic interpretation. Current ESMO guidance generally recommends planning according to a reliable recurrent-disease biopsy when ER, PR or HER2 differs importantly from the primary tumour. Before adding or removing a major treatment class, the team should confirm specimen adequacy and testing method and consider tumour heterogeneity, prior treatment, previous reliable positive results and the pattern of response.

 

A surprising, borderline or technically limited result may justify specialist pathology review, repeat testing on the same block, HER2 in situ hybridisation where indicated, or testing of another specimen. A negative result from a small or compromised sample should not automatically erase a previous high-quality positive result without review.

 

Understanding HER2-Positive, HER2-Low and HER2-Ultralow Results

 

HER2 terminology has become more detailed because some antibody-drug conjugates can be effective in cancers that are not conventionally HER2-positive. These categories should be explained carefully.

 

HER2-positive disease

 

HER2-positive breast cancer has HER2 overexpression or gene amplification meeting accepted pathology criteria. HER2-positive status may make a patient eligible for established HER2-directed treatment, subject to the patient’s previous therapy, organ function and the medicine’s local indication.

 

HER2-low expression

 

HER2-low generally means an immunohistochemistry result of IHC 1+, or IHC 2+ with negative in situ hybridisation. It does not meet the criteria for HER2-positive disease. The term is used to identify potential eligibility for certain antibody-drug conjugates and is not a separate intrinsic breast-cancer subtype.

 

HER2-ultralow expression

 

HER2-ultralow is a treatment-linked term currently used for an IHC 0 result with detectable membrane staining in the setting of the relevant hormone-receptor-positive indication. It should not be extrapolated automatically to every subtype, medicine or country.

 

ASCO/CAP has not created HER2-low or HER2-ultralow as new formal HER2 interpretive categories. Distinguishing IHC 0 from 1+, and no membrane staining from very faint membrane staining, can be difficult and may be affected by specimen age, fixation, tumour heterogeneity and treatment. Eligibility that depends on this distinction may justify review by a breast pathologist using a suitable specimen. HER2 expression is assessed principally by validated pathology methods, not by NGS alone, and the oncologist must verify the current medicine indication in the treating country.

 

Tissue NGS and Liquid Biopsy

 

Next-generation sequencing, or NGS, can examine many cancer-related genes in one analysis. It may identify alterations associated with an approved treatment, a resistance mechanism or a clinical trial. It may also find changes that are not currently actionable.

 

NGS is most useful when the result has a realistic possibility of influencing a decision. Ordering the largest available panel without a defined clinical question may consume tissue, delay care and create findings that are difficult to interpret.

 

Tissue-based NGS

 

Tissue NGS analyses DNA and, on some platforms, RNA from a tumour specimen. A recent metastatic sample may better represent the current disease than an older primary tumour block, particularly after several lines of therapy.

 

Advantages of tissue include:

 

  • direct confirmation that tumour is present;
  • correlation with histology and immunohistochemistry;
  • the possibility of DNA and RNA analysis;
  • assessment of copy-number changes and some fusions;
  • use of the same sample for ER, PR, HER2 and other pathology tests; and
  • a potentially stronger tumour signal than blood when circulating tumour DNA is low.

Limitations include procedural risk, insufficient tumour, poor DNA or RNA quality, and sampling of only one tumour area. Archived tissue may be usable, but age, storage, prior processing and tumour content affect performance.

 

Blood-based liquid biopsy

 

A liquid biopsy usually analyses circulating tumour DNA, or ctDNA, within a blood sample. It can be useful when tissue is unavailable, a biopsy is unsafe, a rapid molecular assessment is needed or acquired resistance is being investigated.

 

Blood testing is less invasive and may capture alterations released by more than one disease site. It is also easier to perform again when serial testing has a clear clinical purpose.

 

Its central limitation is sensitivity. Some tumours release little DNA into the blood. A negative or non-informative result therefore does not prove that an alteration is absent. When the result matters and tissue can be obtained safely, a negative plasma result may need follow-up with tissue testing.

 

Blood tests also detect DNA from blood-forming cells. Age-related clonal haematopoiesis can create findings that did not originate in the cancer. Laboratories and clinicians must recognise this possibility.

 

When both approaches may be useful

 

Tissue and liquid biopsy are complementary rather than interchangeable. A combined or sequential approach may be considered when:

 

  • blood testing is performed while a tissue biopsy is being arranged;
  • plasma identifies a finding that requires confirmation;
  • plasma is negative but a target remains clinically suspected;
  • tissue is limited or fails quality control;
  • an old tissue result does not explain current resistance;
  • different disease sites appear to behave differently; or
  • the team needs both current histology and a broader molecular picture.

Liquid biopsy generally does not replace tissue when the diagnosis, tumour origin or receptor status is uncertain. It should also not be described as a routine screening test for everyone with metastatic breast cancer.

 

For a fuller technical comparison, see Recmed’s guide to tissue biopsy versus liquid biopsy for NGS.

 

Biomarkers That May Influence Treatment

 

The clinically relevant tests depend on breast cancer subtype, previous therapy and available treatments. Not every patient needs every biomarker, and not every positive result leads to an approved medicine.

 

PIK3CA, AKT1 and PTEN

 

Alterations in the PI3K-AKT pathway may support specific targeted options in hormone-receptor-positive, HER2-negative metastatic disease after appropriate prior treatment. The exact alteration, assay, line of treatment and local medicine label matter. A broad statement that any PI3K-pathway change is actionable would be inaccurate.

 

ESR1

 

ESR1 mutations may emerge during aromatase-inhibitor-based therapy and can indicate acquired endocrine resistance. At recurrence or progression, ctDNA is often the preferred practical method; if no ESR1 mutation is detected, repeat testing later may be appropriate because the mutation can emerge over time. A qualifying result may support an oral selective oestrogen-receptor degrader where approved. In the United States, a separate accelerated-approval pathway now permits camizestrant with the existing CDK4/6 inhibitor when a qualifying ESR1 mutation is detected by serial ctDNA before radiographic progression. That indication is assay-, regimen- and jurisdiction-specific, and continued approval may depend on confirmatory benefit; it should not be generalised into routine treatment changes based on any ctDNA result.

 

BRCA1, BRCA2 and PALB2

 

A pathogenic or likely pathogenic germline BRCA1 or BRCA2 variant may affect PARP-inhibitor eligibility in HER2-negative metastatic breast cancer and has implications for biological relatives. Germline PALB2 and other inherited genes may also be clinically important, but their evidence base and treatment indications are not identical to established germline-BRCA medicine labels.

 

A tumour NGS report can suggest a possible inherited alteration, but it cannot always establish that the change is germline. Confirmatory testing using a non-tumour sample and genetic counselling may be needed.

 

PD-L1

 

PD-L1 testing can be relevant in selected triple-negative metastatic breast cancer when a checkpoint inhibitor is being considered. The approved assay, scoring method, specimen and threshold are tied to the medicine and jurisdiction. A PD-L1 result should not be transferred from one treatment indication to another without verification.

 

PD-L1 expression may vary by tumour site and over time. A negative liver specimen may not always answer the entire question, but a positive result does not guarantee response either. The oncology team should use an assay and sample accepted for the intended treatment.

 

MSI, MMR and tumour mutational burden

 

Microsatellite instability-high status, mismatch-repair deficiency and high tumour mutational burden are uncommon in breast cancer. In a qualifying case, they may support a tumour-agnostic treatment or clinical trial where supported by a current local indication. They should not be presented as common explanations for immunotherapy eligibility in breast cancer.

 

Rare fusions and other alterations

 

Rare findings such as an NTRK fusion may support use of a tumour-agnostic targeted therapy. Other alterations may be relevant only in a clinical trial or have uncertain significance. RNA-based testing can be important for some fusions, and not every DNA-only panel will detect them reliably.

 

NGS Does Not Replace HER2 Expression Testing

 

NGS may detect ERBB2 amplification or mutation, but it does not replace validated HER2 immunohistochemistry and in situ hybridisation for standard breast-cancer classification. Likewise, PD-L1 and ER or PR status generally require pathology-based assessment.

 

Germline Testing Is Different from Tumour Profiling

 

Tumour profiling mainly looks for alterations within cancer cells. Germline testing looks for inherited variants present throughout the body. The tests answer different questions even when they include some of the same genes.

 

For patients with recurrent or metastatic breast cancer who could be candidates for a PARP inhibitor, current ASCO–SSO guidance recommends offering BRCA1/2 germline testing regardless of family history. Age, ancestry, personal and family history, previous testing and counselling remain relevant when deciding whether broader multigene testing is appropriate and when interpreting hereditary risk.

 

An inherited result may:

 

  • influence treatment;
  • affect future cancer-risk management;
  • have implications for biological relatives;
  • require confirmatory testing or family testing; and
  • raise psychological, privacy and insurance questions that should be discussed appropriately.

Patients should be offered clear pre-test and post-test information. A variant of uncertain significance should not be treated as a harmful mutation or used alone to make irreversible medical decisions.

 

Interpreting NGS Through a Molecular Tumour Board

 

An NGS report is not a treatment plan. It is a technical document that must be interpreted in the context of the diagnosis, current disease, previous treatments and available evidence.

 

The report may classify findings as:

 

  • linked to a standard treatment for that breast cancer subtype;
  • associated with a treatment under particular prior-therapy conditions;
  • relevant to a clinical trial;
  • supported only by early or indirect evidence;
  • related to resistance rather than sensitivity;
  • potentially inherited; or
  • a variant of uncertain significance.

The term “actionable” can be misleading if it is used without explanation. A molecular alteration may be biologically interesting but not actionable for the patient because the matched medicine is unapproved for breast cancer, unavailable in the treating country, unsuitable after prior toxicity, contraindicated by organ function or supported only by weak evidence.

 

A molecular tumour board can bring together medical oncology, pathology, genetics, molecular diagnostics, radiology and other specialists. It may help determine:

 

  • whether the alteration is genuine and adequately detected;
  • whether the sample represents the current disease;
  • how strong the clinical evidence is;
  • whether confirmatory testing is needed;
  • whether a standard treatment should take priority;
  • whether the finding suggests inherited risk;
  • whether a suitable trial exists; and
  • whether the potential benefit justifies risk, cost and travel.

Patients should receive a written interpretation in plain language. The team should explain what was not detected and what the test could not reliably assess as carefully as what it did find. Failure to identify an actionable alteration does not mean that no effective standard treatment exists.

 

Systemic Treatment Is Planned by Breast Cancer Subtype

 

Systemic treatment reaches cancer cells throughout the body and remains the foundation of care for most patients with breast cancer liver metastases. The plan is based on tumour biology rather than the liver alone.

 

Hormone-receptor-positive, HER2-negative disease

 

When the cancer is ER-positive or PR-positive and HER2-negative, endocrine-based treatment is often preferred if there is no visceral crisis and the disease remains endocrine-sensitive. A common initial strategy combines endocrine therapy with a CDK4/6 inhibitor, subject to menopausal status, prior treatment, contraindications and local approval.

 

At progression, options may depend on:

 

  • which endocrine agents and CDK4/6 inhibitor were previously used;
  • how long the cancer was controlled;
  • ESR1, PIK3CA, AKT1 or PTEN findings where relevant;
  • germline BRCA1 or BRCA2 status;
  • HER2-low or HER2-ultralow expression;
  • prior chemotherapy or antibody-drug conjugates;
  • liver, bone-marrow and kidney function;
  • symptoms and need for rapid shrinkage; and
  • treatment availability in the patient’s country and Türkiye.

Later strategies may include another endocrine-targeted combination, a mutation-directed therapy, a PARP inhibitor for a qualifying inherited alteration, an antibody-drug conjugate or chemotherapy. The sequence is not identical for every patient and changes as evidence and approvals evolve.

 

Chemotherapy may be appropriate even without formal visceral crisis when endocrine-resistant disease, rapid progression, high symptom burden or previous treatments make endocrine therapy unlikely to provide adequate control. The decision should be clinical, not based on the mere presence of a liver lesion.

 

HER2-positive disease

 

HER2-positive metastatic breast cancer is treated with HER2-directed systemic therapy. Treatment options may include HER2-targeted antibodies, antibody-drug conjugates, tyrosine-kinase inhibitors and chemotherapy combinations.

 

As of November 2026, current ESMO guidance recognises both a taxane plus trastuzumab and pertuzumab, and trastuzumab deruxtecan plus pertuzumab, as first-line frameworks for appropriate HER2-positive metastatic disease. The latter received US FDA approval in December 2025. The choice and later sequencing depend on prior exposure, timing of relapse, central-nervous-system disease, cardiac and pulmonary risk, national authorisation, access and patient preference; experience after the newer first-line regimen is still evolving.

 

Sequence depends on:

 

  • previous HER2-directed therapy in the early or metastatic setting;
  • how soon the disease recurred after adjuvant treatment;
  • prior response and toxicity;
  • presence of brain metastases;
  • heart function;
  • lung and liver function;
  • current symptoms; and
  • the medicines approved and accessible in the treating country.

A new biopsy may be especially important if an old HER2-negative cancer appears to have changed or if a prior HER2-positive cancer now tests negative. The team should verify sample quality and review the full history before removing or adding a major treatment class.

 

Triple-negative breast cancer

 

Triple-negative breast cancer is negative for ER and PR and is not HER2-positive by standard criteria. Systemic options may include chemotherapy, an immune-checkpoint inhibitor in a qualifying PD-L1-positive setting, an antibody-drug conjugate, a PARP inhibitor for a qualifying germline BRCA alteration, or a tumour-agnostic option for a rare biomarker.

 

In the United States, June 2026 approvals added first-line sacituzumab govitecan as monotherapy for patients who are not candidates for PD-1 or PD-L1-directed therapy and in combination with pembrolizumab for PD-L1-positive disease meeting the specified combined-positive-score threshold. These are jurisdiction- and indication-specific options; the accepted assay, previous-treatment conditions, safety profile and local authorisation must be checked.

 

Treatment selection depends on previous perioperative and metastatic therapy, disease-free interval, PD-L1 assay and score, germline findings, HER2 expression category, symptoms and organ function. If immunotherapy is being considered, the exact assay and local indication must be confirmed. A general statement that all triple-negative cancers respond to immunotherapy would be unsafe.

 

Recmed’s separate guide explains immunotherapy eligibility, biomarker testing and treatment planning in more detail.

 

HER2-low and treatment-linked HER2-ultralow expression

 

HER2-low expression can affect antibody-drug-conjugate eligibility in both hormone-receptor-positive and hormone-receptor-negative metastatic breast cancer after the prior treatment specified by the local label. The current HER2-ultralow indication applies to hormone-receptor-positive disease in the relevant regulatory setting and should not be extrapolated to triple-negative breast cancer.

 

Eligibility and sequence depend on validated pathology, previous systemic treatment, national approval and the patient’s fitness for treatment. Some antibody-drug conjugates can cause interstitial lung disease or pneumonitis, including serious cases, so baseline assessment, symptom education and prompt investigation of new respiratory symptoms are important.

 

Why Liver Metastases Do Not Automatically Mean Chemotherapy

 

Patients sometimes hear that any spread to the liver requires immediate chemotherapy. That is not universally correct.

 

Chemotherapy can be essential when the disease is rapidly progressive, endocrine resistant, causing major symptoms or threatening organ function. It may also be the standard backbone for a particular subtype or treatment line.

 

However, a patient with hormone-receptor-positive, HER2-negative disease, preserved liver function and no visceral crisis may receive endocrine therapy combined with a targeted agent. A patient with HER2-positive disease may receive a HER2-directed regimen. A patient with qualifying triple-negative disease may receive immunotherapy with chemotherapy. The most appropriate approach is the one supported by the cancer subtype and clinical situation.

 

Even when chemotherapy is indicated, the regimen is individualised. Combination chemotherapy may be used when a faster and deeper response is urgently needed, but a single agent can be preferable in other situations to reduce toxicity and preserve future options.

 

The treating oncologist should explain:

 

  • why the chosen treatment fits the current subtype;
  • how quickly a response is needed;
  • what alternatives exist;
  • how effectiveness will be measured;
  • what toxicities require urgent attention; and
  • what the next option would be if the disease does not respond.

How Treatment Sequencing Is Decided

 

Metastatic breast cancer treatment is a sequence rather than a single decision. The next treatment decision depends on the treatments already received and their outcomes.

 

The oncology team considers:

 

  • receptor and molecular results;
  • adjuvant and metastatic treatments already received;
  • time to recurrence and duration of previous response;
  • reasons a prior treatment stopped;
  • cumulative toxicities, including heart, nerve, lung and bone-marrow effects;
  • pace and distribution of progression;
  • whether progression is limited to one site or widespread;
  • liver function and other organ reserve;
  • daily activity and nutritional status;
  • coexisting conditions and medicines;
  • pregnancy or fertility considerations where relevant;
  • patient goals and tolerance for risk;
  • access, reimbursement and regulatory status; and
  • trial availability.

An alteration found by NGS does not necessarily move a targeted medicine ahead of an established standard treatment. Evidence level and line of therapy matter. Likewise, a medicine approved in the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand or one African country may not have the same indication, availability or reimbursement in Türkiye or another country.

 

The written plan should identify the treatment, purpose, baseline tests, schedule, monitoring, major risks and criteria for changing course. For an international patient, it should also state what can be delivered locally and who will manage complications after returning home.

 

Liver-Directed Treatment: Who May Be Considered

 

Local treatment aims at one or more liver lesions. It does not replace systemic therapy for disease elsewhere. Options can include surgical resection, thermal ablation, stereotactic body radiotherapy, selective internal radiation therapy or radioembolisation, and transarterial chemoembolisation. Availability and expertise vary.

 

There is no universally accepted indication for routine liver surgery or ablation in metastatic breast cancer. The evidence base is substantially less developed than that for colorectal liver metastases. Much of the published breast-cancer evidence is retrospective and affected by selection: patients chosen for procedures often have more favourable disease than those who are not.

 

In NRG-BR002, adding metastasis-directed treatment to systemic therapy in selected patients with a controlled primary tumour, no progression on first-line systemic therapy and up to four extracranial metastases did not improve progression-free or overall survival. The study was not liver-specific, but it argues against routine ablation of all metastases in oligometastatic breast cancer. Local treatment should therefore be an individual multidisciplinary option for a defined local-control or palliative purpose, not a standard curative strategy.

 

Situations that may prompt discussion

 

A specialised tumour board may consider local treatment when there is:

 

  • one or a limited number of liver lesions;
  • no extrahepatic disease or well-controlled disease elsewhere;
  • a long interval from the original diagnosis;
  • favourable response or durable control on systemic therapy;
  • disease confined mainly to the liver;
  • one resistant liver focus while other disease remains controlled;
  • a lesion causing or likely to cause a local complication;
  • a technically achievable treatment with acceptable risk; and
  • a clear purpose understood by the patient.

These features do not guarantee benefit. Tumour biology and disease behaviour may be more important than lesion count alone.

 

Surgery

 

Liver resection is reserved for highly selected patients in experienced centres. The team evaluates the number and position of lesions, ability to remove all visible disease, future liver volume, extrahepatic control, previous response, surgical risk and the expected role of continued systemic therapy.

 

Surgery can remove visible liver disease, but it cannot prove that microscopic cancer is absent elsewhere. It should not be described as curative for metastatic breast cancer. A patient should understand the uncertainty of benefit, expected recovery, possible complications and alternatives.

 

Thermal ablation

 

Radiofrequency or microwave ablation uses heat to destroy a lesion. It may be considered for selected small tumours in locations where a safe treatment margin can be achieved. Lesions near large blood vessels, bile ducts, the diaphragm or other organs may be harder or unsafe to ablate with an adequate margin. Local recurrence is possible, and continued systemic management remains important.

 

Stereotactic radiotherapy

 

Stereotactic body radiotherapy, also called stereotactic ablative radiotherapy in some countries, delivers focused radiation over a limited number of sessions. It may be an option when surgery or ablation is unsuitable, for oligometastatic or oligoprogressive disease, or for symptom control. Liver reserve, lesion size, location and prior radiation affect safety.

 

SIRT, TARE and TACE

 

Selective internal radiation therapy, also called transarterial radioembolisation or TARE, and transarterial chemoembolisation deliver treatment through the hepatic arterial system. Evidence in breast-cancer liver metastases is predominantly retrospective and drawn from selected salvage populations; a randomised overall-survival benefit has not been established. These procedures are not routine substitutes for effective systemic therapy. They may be discussed in a specialist multidisciplinary setting for selected liver-dominant, treatment-refractory or symptomatic disease, or within a clinical trial, after review of liver reserve, extrahepatic disease, previous therapy and procedure-related hepatotoxicity.

 

Questions before any local procedure

 

Patients should ask:

 

  • What is the exact aim of the procedure?
  • Is disease elsewhere controlled?
  • What evidence supports this option in my situation?
  • Will systemic treatment continue or change?
  • Could the procedure delay a more effective systemic treatment?
  • What are the risks to liver function?
  • How will response be assessed?
  • What happens if new lesions appear?
  • Has the case been discussed by medical oncology, liver surgery, interventional radiology and radiation oncology?

Surgery to the Primary Breast Tumour in Stage IV Disease

 

When breast cancer is metastatic at first diagnosis and the intact breast tumour is asymptomatic, routine locoregional treatment cannot be recommended to improve survival. Systemic therapy usually takes priority because it treats disease throughout the body.

 

Breast surgery or radiotherapy may be appropriate to control bleeding, ulceration, infection, pain or another local complication, or after multidisciplinary discussion for an individual local-control goal that is important to the patient. Technical resectability alone is not an indication. Any treatment interruption, anaesthetic risk, wound-healing risk and effect on systemic therapy should be considered, and the patient should be told that an overall-survival benefit has not been established.

 

Monitoring Treatment and Deciding Whether It Is Working

 

Monitoring should begin with a clear baseline. The team records measurable disease, symptoms, performance status, laboratory values and treatment-related risks before starting therapy.

 

Follow-up may include:

 

  • clinical review and symptom assessment;
  • full blood count and organ-function tests;
  • repeat CT, MRI or other appropriate imaging;
  • cardiac, lung or other treatment-specific monitoring;
  • assessment of pain, weight and nutrition;
  • evaluation of adverse effects; and
  • tumour markers when they have a useful supporting role.

Current ESMO guidance recommends response assessment approximately every two to four months, individualised to treatment, disease pace, symptoms and the clinical question. More frequent routine imaging has not shown an overall-survival benefit and can add emotional, financial and radiation burden. The same imaging method and comparable technique should be used whenever possible, with earlier assessment when symptoms or laboratory findings suggest progression or a complication.

 

Radiologists may use standard response criteria, but measurements are only part of the decision. A patient’s symptoms, organ function and new lesions matter. Bone disease and some treatment effects can be difficult to classify by size alone.

 

An isolated liver lesion may enlarge while disease elsewhere remains controlled. This mixed or oligoprogressive pattern can prompt re-biopsy, a change in systemic treatment, or local treatment of the resistant focus while continuing an otherwise effective regimen. The decision depends on whether the apparent progression is real, clinically important and technically addressable.

 

ctDNA monitoring is developing rapidly, but it does not generally replace imaging and clinical assessment. Treatment should not be changed solely because a non-specific ctDNA value rises. An exception may exist within a validated, medicine-specific pathway—such as the current US ESR1-guided accelerated-approval setting—when the exact assay, mutation, regimen and eligibility criteria are met.

 

If the first scan appears worse shortly after starting treatment, the team should interpret it in context rather than assuming either failure or a temporary immune effect. True pseudoprogression is not common enough in breast cancer to justify continuing an ineffective treatment without careful review.

 

Supportive and Palliative Care Are Part of Active Treatment

 

Supportive and palliative care should not be reserved only for the final stage of illness. They can be provided alongside anticancer treatment to improve comfort, function and decision-making.

 

Support may address:

 

  • pain;
  • nausea, appetite loss and weight change;
  • fatigue and sleep problems;
  • anxiety, depression and family distress;
  • fluid accumulation;
  • itching or jaundice;
  • bowel problems;
  • treatment-related neuropathy;
  • menopausal and sexual health concerns;
  • bone health;
  • nutrition;
  • work, travel and financial concerns; and
  • advance-care planning when the patient wishes to discuss it.

Symptoms should be investigated rather than assumed to be unavoidable. Some arise from the cancer, some from treatment, and others from unrelated conditions. Early management can make it easier to continue useful therapy.

 

Symptoms That Require Urgent Medical Attention

 

Patients with liver metastases and those receiving systemic treatment should know whom to contact at any time of day. Severe or rapidly worsening symptoms require local medical assessment; an international online review is not an emergency service.

 

Urgent contact with the oncology team or emergency care may be needed for:

 

  • new or worsening jaundice;
  • dark urine, pale stools or intense generalised itching with jaundice;
  • confusion, unusual drowsiness or a marked change in behaviour;
  • severe or rapidly increasing abdominal pain or swelling;
  • persistent vomiting or inability to keep down fluids;
  • vomiting blood, black stools or other significant bleeding;
  • a temperature of 38.0°C or higher, or the lower threshold specified by the treating clinic, chills or suspected infection—particularly during treatment;
  • new breathlessness, chest pain, fainting or a rapid fall in oxygen level if monitored;
  • sudden weakness or numbness, loss of balance, seizure, severe new headache, speech or vision change, or new loss of bladder or bowel control;
  • rapidly declining daily function;
  • very little urine or signs of severe dehydration;
  • uncontrolled pain; or
  • any treatment-specific warning sign identified by the clinical team.

Jaundice does not always mean that the liver is failing because a bile duct can also be blocked. That distinction requires prompt examination, blood tests and imaging. Similarly, confusion can have metabolic, infectious, medication-related or neurological causes. Patients should not attempt to diagnose or manage these problems from an internet article.

 

People who are medically unstable should not delay urgent local treatment or fly to Türkiye while waiting for a second opinion. Fitness to travel, access to medicines in transit, infection risk, oxygen needs, thrombosis risk and an emergency plan should be reviewed before any international journey.

 

Multidisciplinary Planning for Breast Cancer with Liver Metastases in Türkiye

 

Breast cancer with liver metastases should not be planned around one test, one medicine or one procedure. The most useful review brings the current pathology, the full treatment history, recent imaging, organ function and the patient’s priorities into the same discussion.

 

For an international patient considering care in Türkiye, the appropriate team may include:

 

  • A medical oncologist experienced in metastatic breast cancer
  • A breast pathologist or molecular pathologist
  • A radiologist and, when needed, an interventional radiologist experienced in liver imaging and biopsy
  • A radiation oncologist when stereotactic body radiotherapy may be relevant
  • A hepatobiliary surgeon when resection is being discussed for a highly selected case
  • Genetic counselling and supportive-care specialists when relevant

The medical oncologist normally leads systemic treatment planning. A liver surgeon or interventional specialist should not assess a scan in isolation and recommend a local procedure without considering whether disease is present elsewhere, whether the cancer is responding to current systemic treatment, and whether the procedure has a realistic clinical purpose.

 

Not every specialist or procedure is required. The review should answer defined questions:

 

  • Are the diagnosis and breast origin of the liver lesion sufficiently confirmed, and is a new biopsy justified?
  • Have oestrogen receptor, progesterone receptor and HER2 been reassessed when appropriate?
  • Could tissue-based or blood-based molecular testing alter the next treatment decision?
  • Is the disease limited to the liver, liver-dominant or clearly present in several organs?
  • Is systemic therapy the immediate priority?
  • Would surgery, ablation, stereotactic radiotherapy or another liver-directed approach provide a reasonable prospect of benefit in this particular situation?
  • What monitoring and follow-up are required?

A preliminary opinion can often be prepared before travel. The final plan may change after examination, imaging review, blood tests, pathology review or biopsy.

 

Recmed’s broader cancer treatment planning guide for Türkiye explains why diagnosis review and staging should come before hospital or price comparisons.

 

Step-by-Step Review Before Booking Travel

 

Step 1: Define the immediate medical question

 

The review should begin with a concise question rather than a general request for “the best treatment.” Examples include:

 

  • Should a newly identified liver lesion be biopsied, and would the resulting sample likely be adequate for receptor reassessment and NGS?
  • Could a change in ER, PR or HER2 alter treatment?
  • Is a liquid biopsy useful after progression on endocrine or targeted therapy?
  • Is the patient being considered for the appropriate next line of systemic treatment?
  • Is local liver-directed treatment medically reasonable?
  • Can the plan continue safely in the patient’s home country?

Step 2: Build a dated disease timeline

 

Prepare a one- to two-page chronology containing:

 

  • Date of the original breast cancer diagnosis
  • Side and location of the primary tumour
  • Histological type and grade
  • Original ER, PR and HER2 results
  • Initial stage
  • Dates of surgery and all systemic or radiation treatments, including doses when available
  • Best response and the reason each treatment stopped
  • Date the liver lesions were first detected
  • Other metastatic sites, if any
  • Date and site of the most recent biopsy and imaging
  • Current symptoms, medicines and performance in daily activities

Step 3: Check the completeness and usability of the records

 

The team should identify missing information before travel. A pathology report without relevant immunohistochemistry, a scan report without DICOM images, or an NGS report without the specimen date may be insufficient.

 

Step 4: Select the appropriate lead specialist

 

The case should normally be reviewed first by a medical oncologist experienced in metastatic breast cancer. Other specialists should be added according to the question. A patient asking about liver surgery may still need systemic treatment reassessed first. A patient seeking NGS may first need pathology confirmation that the sampled tissue is metastatic breast cancer.

 

Step 5: Decide whether pathology or molecular work is required

 

The preliminary review should state whether the team recommends:

 

  • Review of existing pathology slides or paraffin blocks
  • Repeat ER, PR and HER2 testing
  • A new image-guided core biopsy
  • Tissue-based NGS
  • Blood-based liquid biopsy
  • Separate germline genetic testing
  • Additional immunohistochemistry, in situ hybridisation or another validated test

The Recmed guide to tissue biopsy and liquid biopsy for NGS provides a more detailed comparison. Testing should be ordered to answer a clinical question, not simply to produce a longer laboratory report.

 

Step 6: Obtain a written preliminary proposal

 

The proposal should distinguish between:

 

  • What is already established from the submitted records
  • What remains uncertain
  • Which examinations are required in Türkiye
  • Which recommendations are conditional on new results
  • Whether the plan is systemic treatment, local treatment, supportive care or a sequence of these approaches
  • How response will be monitored

The proposal should state whether the next step requires travel or can begin with remote review.

 

Step 7: Confirm medical stability and travel requirements

 

The home doctor should assess fitness to fly and whether treatment can safely wait for travel.

 

Severe or rapidly worsening symptoms should be assessed locally without waiting for an international opinion. These may include increasing shortness of breath, confusion, fainting, uncontrolled pain, persistent vomiting, fever, bleeding, jaundice, marked abdominal swelling or a sudden decline in the ability to walk, eat or perform daily activities.

 

Step 8: Plan continuity before the first treatment

 

Before treatment begins in Türkiye, the team should identify:

 

  • Who will monitor the patient after returning home
  • Which laboratory tests are needed and how often
  • Where the planned medicine can be obtained
  • Whether the same formulation and dose are available at home
  • Who will respond to urgent side effects
  • How imaging will be shared between teams
  • Whether future doses must be administered in Türkiye or can be administered by a local oncology unit

Continuity should be part of the first written plan, not an afterthought at discharge.

 

Complete Medical Records Checklist

 

Patients do not need to recreate tests that already exist, but the receiving team needs complete and readable copies. Documents should ideally be organised by date and accompanied by a short index.

 

Pathology reports and material

 

Provide:

 

  • The original breast biopsy report
  • The breast surgery pathology report, if surgery was performed
  • Lymph-node pathology reports
  • Reports from any liver or other metastatic-site biopsy
  • Histological type, grade and specimen date
  • ER and PR results, including the percentage or scoring method when reported
  • HER2 immunohistochemistry result
  • HER2 in situ hybridisation result when IHC was equivocal or ISH was otherwise performed
  • Ki-67 or other reported proliferation data, with the understanding that its use and interpretation vary
  • PD-L1, MSI, MMR, TMB or other biomarker reports when available
  • Cytology reports, if relevant
  • Molecular or NGS reports, including the laboratory, panel, specimen source and specimen date
  • Germline genetic test results and genetic-counselling notes, when applicable

If a pathology review or new molecular test may be needed, also confirm where the following are stored:

 

  • Formalin-fixed paraffin-embedded tissue blocks
  • Unstained slides
  • Previously stained histology and immunohistochemistry slides
  • Digital pathology files, if available

Do not ship slides or blocks until the receiving hospital or laboratory provides written instructions. The team should confirm the required number and type of slides, packaging, labelling, courier conditions, customs documentation, return policy and chain-of-custody process. Every specimen label must match the patient identifiers and pathology report.

 

Imaging reports and original files

 

Provide the reports and original DICOM files for relevant studies, including:

 

  • Contrast-enhanced CT
  • Liver MRI
  • PET-CT when performed
  • Bone scan when performed
  • Breast imaging relevant to the current question
  • Brain MRI or other site-specific imaging when clinically indicated
  • Images from procedures such as liver biopsy, ablation or radiotherapy planning when available

Screenshots, photographs of a monitor and PDF reports alone do not allow a radiologist to fully review the examination. DICOM files should be exported from the imaging centre through a secure upload link, portal, CD, DVD or encrypted storage medium accepted by the receiving hospital.

 

Include the baseline scan before current treatment and the latest comparison study.

 

Complete treatment history

 

Provide:

 

  • Operation notes and discharge summaries
  • Chemotherapy protocols, drug names, doses, cycle dates and reason for stopping
  • Endocrine-therapy names and dates
  • CDK4/6 inhibitor or other targeted-therapy details
  • HER2-directed treatment details
  • Antibody-drug conjugate treatment details, if received
  • Immunotherapy details, including the last dose and any immune-related complication
  • Radiotherapy site, total dose, number of fractions and treatment dates
  • Liver-directed procedure reports
  • Previous treatment responses and progression dates
  • Important toxicities, dose reductions, delays or hospital admissions

Because brand names differ, include each medicine’s international nonproprietary name (INN) and the prescription when possible.

 

Current health information

 

Provide:

 

  • Recent full blood count
  • Liver and kidney function results
  • Electrolytes and other relevant laboratory tests
  • Current height and weight
  • Current medication and supplement list
  • Drug allergies
  • Major heart, lung, kidney, liver, neurological or autoimmune conditions
  • History of blood clots or bleeding problems
  • Current pain medicines and anti-nausea medicines
  • Pregnancy status when relevant
  • Recent infection history
  • Description of current symptoms and daily activity level

If there is ascites, biliary obstruction, infection, a recent blood clot or another active complication, state this clearly at the beginning of the request.

 

Document quality, language and file organisation

 

Use clear scans rather than cropped mobile-phone photographs. Each file name should contain the date, document type and institution, for example:

 

  • 2026-09-14_Liver_MRI_Report
  • 2026-07-02_Liver_Biopsy_Pathology
  • 2026-07-02_ER_PR_HER2_Results
  • 2026-10-05_NGS_Report

English-language records may be reviewable without translation, but the institution may request certified translations for consent, complex terminology or documents in another language. Confirm the requirements before paying to translate a full set of documents.

 

Send sensitive records only by an approved method and with the patient’s consent for international transfer and review.

 

Recmed’s cancer second-opinion records guide explains the broader document-transfer, DICOM and pathology-material workflow.

 

Patients may also request a preliminary records review.

 

What the Written Treatment Proposal Should Answer

 

A useful proposal should be specific enough to support a decision while remaining honest about unresolved questions.

 

Diagnosis and testing

 

Ask the team to state:

 

  • What diagnosis and current stage are supported by the records?
  • Is the liver disease sufficiently confirmed as metastatic breast cancer?
  • Is pathology review required?
  • Is a new biopsy recommended, and why?
  • Which lesion would be sampled and by what method?
  • What are the expected procedure risks?
  • Are ER, PR and HER2 results current and technically adequate?
  • Which molecular or germline tests are recommended?
  • How could each proposed test change management?
  • What will happen if tissue is insufficient or a liquid biopsy is negative?

Treatment strategy

 

The proposal should explain:

 

  • The intended treatment goal
  • The recommended systemic treatment class or regimen
  • Why it is appropriate for the current subtype and prior treatment history
  • Whether treatment is standard, off-label or part of a clinical trial
  • Whether a liver-directed treatment is being considered
  • The purpose of any local procedure
  • Whether systemic therapy comes before, after or instead of the local procedure
  • How and when response will be assessed
  • What circumstances would lead to a dose change, delay or treatment switch
  • Which supportive medicines and monitoring are required

Patients should be cautious if a proposal promises that removal of visible liver lesions will cure metastatic breast cancer, or if it recommends surgery or ablation without reviewing disease outside the liver and the current systemic-treatment plan.

 

Logistics and follow-up

 

The proposal should also state:

 

  • Which appointments are planned
  • The expected sequence of consultations, tests and procedures
  • The estimated minimum stay in Türkiye
  • Whether a companion is advisable
  • Whether treatment can begin during the same visit
  • When the patient may be medically fit to fly home
  • Which follow-up can take place remotely
  • Which documents will be provided at discharge
  • Who will communicate with the oncologist at home

Cost Factors and the Itemised Estimate

 

There is no single price for treating metastatic breast cancer with liver involvement. The cost depends on the information already available, the tests that are medically justified, the selected treatment and the duration and setting of care.

 

Diagnostic and planning costs

 

These may include:

 

  • Medical-oncology consultation
  • Multidisciplinary review
  • Radiology review of outside imaging
  • Pathology review
  • Shipping and handling of slides or blocks
  • Repeat immunohistochemistry or in situ hybridisation
  • Image-guided liver biopsy
  • Interventional-radiology, anaesthesia and hospital charges
  • Tissue-based NGS or liquid biopsy
  • Separate germline genetic testing and counselling
  • CT, MRI, PET-CT or other restaging imaging
  • Laboratory tests and cardiac assessment when required

Treatment costs

 

These may be affected by:

 

  • The medicine or combination selected
  • Dose, which may depend on body size or a fixed protocol
  • Number and frequency of cycles
  • Day-unit, pharmacy and infusion charges
  • Supportive medicines
  • Central venous access when required
  • Monitoring and repeat imaging
  • Surgery, ablation, radiotherapy or another liver-directed procedure in selected cases
  • Hospital admission or intensive monitoring
  • Management of side effects or complications

Travel-related costs

 

These may include:

 

  • Accommodation
  • Airport and local transfers
  • Interpreter support
  • A companion’s expenses
  • Extension of stay if tests or recovery take longer than expected
  • Return travel for additional cycles or follow-up

Request a dated, written, itemised estimate. It should identify:

 

  • Currency
  • Validity period
  • Services included
  • Services excluded
  • Whether quoted drug costs cover one dose, one cycle or the proposed course
  • Whether pathology, imaging and laboratory work are separate
  • Whether taxes, professional fees and hospital charges are included
  • Deposit and cancellation conditions
  • Circumstances that may change the estimate

Compare estimates using the same treatment, dose, number of cycles, testing, hospital services and follow-up assumptions.

 

Insurance coverage varies by policy and country. Patients should obtain written confirmation from their insurer rather than assume that international cancer care, molecular testing or complications will be covered.

 

International Travel, Visa and Continuity Considerations

 

Country-Specific Travel Planning

 

This guidance is intended for any patient seeking an English-language review, including patients from the United States, Canada, the United Kingdom, Ireland, Australia, New Zealand and countries across Africa where English is widely used in healthcare and international communication. It should not be interpreted as one travel pathway for every country.

 

Visa rules, transit requirements, airline policies, insurance coverage, document certification and medicine availability differ by nationality, residence and route. Requirements can also change. Patients should verify the current rules with the relevant Turkish consular authority, transit-country authorities and airline before purchasing non-refundable tickets.

 

Patients travelling from countries across Africa may face very different visa, flight, sample-shipping and medicine-access arrangements. Planning must use the patient’s actual passport, route, health condition and local oncology resources, not assumptions about an entire region.

 

Medical fitness to travel

 

The home oncology team should assess:

 

  • Current symptoms, performance status and oxygen needs
  • Pain control and risk of a blood clot or bleeding
  • Anaemia, low blood counts or infection
  • Ascites, jaundice or impaired liver function
  • Recent surgery, biopsy or invasive procedure
  • Need for urgent treatment
  • Ability to sit through the planned journey

The airline may require a medical information form, oxygen arrangements or advance approval. A fit-to-fly letter does not guarantee boarding and should be based on a current examination.

 

Carry a medical summary, prescriptions, allergy information, emergency contact details and sufficient essential medicine in labelled packaging. Controlled, injectable or temperature-sensitive products may need additional documentation.

 

Medication access after returning home

 

A treatment plan prepared in Türkiye is practical only if the medicine, monitoring and management of side effects can continue safely.

 

Before starting treatment, confirm:

 

  • Whether the medicine is licensed or otherwise accessible at home
  • Whether the same formulation is available
  • Whether public, private or insurance funding applies
  • Expected procurement time
  • Whether a local oncology unit can administer it
  • Which tests are required before each dose
  • Whether supportive medicines are available
  • Who can manage urgent complications
  • Whether cross-border shipment is lawful and medically appropriate

Do not carry oncology medicines across borders without confirming prescription, customs, storage and transport requirements. Do not change brands, doses or schedules without the treating oncologist’s approval.

 

Shared follow-up with the home oncologist

 

The Turkish team should provide:

 

  • A final diagnosis and staging summary
  • Pathology and biomarker reports
  • Procedure reports
  • Treatment protocol, dose and administration dates
  • Toxicity and dose-modification history
  • Current medication list
  • Required laboratory schedule
  • Imaging schedule and response criteria
  • Warning symptoms and emergency instructions
  • Contact details for clinical communication

The home oncologist should receive these records promptly. Where possible, the two teams should agree who is responsible for prescribing, administering treatment, ordering scans and responding to urgent symptoms.

 

What Recmed Medical Travel Can and Cannot Coordinate

 

Recmed Medical Travel is a medical-travel coordination company. It supports communication and organisation between international patients and licensed healthcare providers in Türkiye.

 

Recmed may coordinate

 

Depending on the case, Recmed may help with:

 

  • Receiving and organising medical records
  • Identifying missing documents
  • Matching the case to an appropriate medical oncologist or multidisciplinary centre
  • Arranging a preliminary records review
  • Coordinating pathology slide or block review
  • Coordinating radiology review
  • Arranging a new biopsy when recommended and ordered by the medical team
  • Coordinating ER, PR, HER2, other biomarker, NGS or germline testing when ordered
  • Arranging an online or in-person consultation
  • Requesting a written preliminary treatment proposal and itemised estimate
  • Scheduling appointments, tests and procedures
  • Assisting with interpreters, accommodation options and local transfers
  • Helping obtain discharge records and follow-up recommendations
  • Supporting communication with the home medical team when authorised by the patient

For a more general explanation of international oncology coordination, see the Recmed cancer treatment guide.

 

Recmed cannot

 

Recmed cannot:

 

  • Diagnose cancer
  • Decide whether a patient needs a biopsy
  • Prescribe medicines
  • Interpret NGS independently, guarantee treatment eligibility, or guarantee response, survival or cure
  • Replace the patient’s medical oncologist
  • Provide emergency medical care
  • Determine fitness to fly or guarantee visa, airline, insurance or medicine access
  • Override hospital, laboratory, customs or pathology-material transport requirements

All diagnostic and treatment decisions must be made by licensed clinicians and healthcare institutions after reviewing the complete case.

 

Questions to Ask the Oncologist

 

Patients may take this list to an online or in-person consultation:

 

  1. Are the liver lesions sufficiently confirmed as breast cancer metastases?
  2. Would a new biopsy change the treatment decision in my case?
  3. Which lesion is safest and most informative to biopsy?
  4. Should ER, PR and HER2 be reassessed?
  5. Is my existing tissue recent and adequate?
  6. Do I need tissue NGS, liquid biopsy, both or neither?
  7. Which molecular findings could realistically change my next treatment?
  8. Do I need separate germline testing and genetic counselling?
  9. If the blood test is negative, should tissue still be tested?
  10. Is my disease liver-only, liver-dominant or present in several organs?
  11. Does liver involvement in my case constitute visceral crisis, or is there time for a records-based review?
  12. What is the recommended systemic treatment and why?
  13. Is liver-directed treatment appropriate, what evidence supports it, and could it interfere with systemic therapy?
  14. How will response and urgent side effects be managed?
  15. Can treatment continue at home? What is included in the written estimate?

Frequently Asked Questions

 

Is Breast Cancer in the Liver the Same as Primary Liver Cancer?

 

No. Breast cancer in the liver is metastatic breast cancer, and its pathology classification and treatment follow its breast origin rather than being managed as primary liver cancer. If the diagnosis or origin of a liver lesion is uncertain, a biopsy may be recommended when it can be performed safely and the result could change treatment.

 

Is a liver biopsy required for every patient with breast cancer liver metastases?

 

No. A biopsy may be recommended when the liver lesions are newly identified, the diagnosis is uncertain, receptor reassessment could change treatment or fresh tissue is needed for a clinically relevant test. It may be unnecessary or unsafe when the diagnosis is already well supported, the result would not change management, or the procedural risk is too high. The decision should be individualised by the oncology and interventional-radiology teams.

 

Why repeat a biopsy when breast cancer has already been diagnosed?

 

The biological characteristics of metastatic disease may differ from those of the original breast tumour. Reassessing ER, PR and HER2 can sometimes alter treatment planning. A biopsy may also confirm that a liver lesion is metastatic breast cancer rather than another condition. However, a new biopsy should have a defined purpose and an acceptable risk.

 

Can the original breast tumour block be used instead of a new liver biopsy?

 

Sometimes. Archived tissue may be suitable for pathology review or molecular testing if it contains enough viable tumour and the material is technically adequate. Older tissue may not reflect changes that developed during treatment. The oncologist and laboratory should decide whether the archived sample can answer the current question.

 

Can liquid biopsy replace a liver biopsy?

 

Not in every situation. A blood-based liquid biopsy can identify selected tumour-related alterations and may be useful when tissue is unavailable or unsafe to obtain, or when a rapid molecular result is needed. It generally cannot replace tissue for confirming histology or performing all receptor and immunohistochemical assessments. A negative blood result may occur when too little tumour DNA is present in the sample.

 

What happens if liquid biopsy is negative?

 

A negative or non-informative result does not prove that the tumour has no relevant alteration. The medical team may review assay quality, tumour burden, timing and prior treatment, and may recommend tissue testing if it is safe and the result could affect treatment.

 

Does NGS choose the best treatment?

 

No. NGS may identify alterations associated with approved treatments, resistance, clinical trials or inherited risk, but many findings are not actionable. A treatment decision also depends on receptor status, previous therapies, disease behaviour, symptoms, organ function, availability and the strength of evidence. NGS supports clinical judgement; it does not replace it.

 

Does finding a mutation guarantee access to a targeted medicine?

 

No. The alteration must be relevant to the breast cancer subtype and current treatment setting. The medicine must also be medically appropriate, available and permitted within the treating jurisdiction. Prior treatment, contraindications, funding and evidence level may affect access.

 

What if the liver biopsy has a different ER, PR or HER2 result?

 

The oncology team should review specimen quality, testing method and the complete treatment history before deciding which result should guide care. Discordant results can be clinically important, but they do not automatically dictate one treatment. In some cases, repeat or confirmatory testing may be needed.

 

Does liver metastasis automatically mean chemotherapy is required?

 

No. The treatment depends on breast cancer subtype, previous therapy, symptoms, pace of progression and organ function. Some patients may receive endocrine and targeted treatment, HER2-directed therapy, an antibody-drug conjugate, chemotherapy, immunotherapy in an eligible setting or another approach. The presence of liver metastases alone is not the same as visceral crisis.

 

Can Stage IV Breast Cancer with Liver Metastases Be Cured?

 

Stage IV breast cancer with liver metastases is generally treated as a disease that is not curable, although systemic treatment may control it for meaningful periods and help preserve quality of life. Rare, highly selected patients may be considered for liver-directed treatment after multidisciplinary review, but these situations do not justify promises of cure. Treatment goals should be individualised according to tumour biology, disease extent, response, symptoms, overall health and the patient’s priorities.

 

What is visceral crisis?

 

Visceral crisis refers to severe organ dysfunction caused by rapidly progressive cancer, not simply the presence of metastases in a visceral organ. It may require urgent systemic treatment. A patient with worsening jaundice, major liver-function impairment or rapid clinical decline should be assessed promptly and should not delay local care while arranging international travel.

 

Can liver surgery or ablation cure metastatic breast cancer?

 

These procedures should not be presented as a guaranteed cure. Systemic therapy remains central because metastatic breast cancer may involve disease beyond what is visible in the liver. Surgery, thermal ablation, stereotactic radiotherapy or another local approach may be discussed for carefully selected patients, usually after multidisciplinary review and with a clearly stated purpose.

 

Can a liver-directed procedure replace systemic treatment?

 

Usually not. A local procedure treats defined liver lesions but does not treat microscopic or known cancer elsewhere in the body. In selected cases, local therapy may complement systemic treatment, address a resistant focus, relieve symptoms or manage limited liver-dominant disease. The sequence should be decided by the multidisciplinary team.

 

Can my case be reviewed before I travel to Türkiye?

 

Often, yes. Records review may identify missing tests, pathology needs and the appropriate specialist. A final plan may still require examination, imaging, laboratory tests or biopsy.

 

How long will I need to stay in Türkiye?

 

The duration depends on the planned consultation, biopsy, testing or treatment. Reporting times vary, so request a case-specific schedule before booking inflexible return travel.

 

Can treatment continue after I return home?

 

Potentially, if the medicine and monitoring are available and a local oncology team accepts care. Confirm this before treatment and obtain written protocols, doses and safety instructions.

 

Request a Metastatic Breast Cancer Case Review

 

Patients considering a specialist review in Türkiye may send Recmed:

 

  • Pathology reports
  • ER, PR and HER2 results
  • Information about available slides or paraffin blocks
  • Latest CT, MRI or PET-CT reports
  • Original imaging in DICOM format
  • Complete treatment history
  • Previous NGS, liquid-biopsy or genetic reports
  • Recent blood tests
  • Current medicines and symptoms
  • The main question they want the oncology team to answer

Recmed can review whether the documentation is complete, coordinate assessment by an appropriate licensed medical team and request a written preliminary plan and itemised estimate. A preliminary review does not guarantee that treatment in Türkiye is indicated.

 

Contact Recmed Medical Travel to request a case review.

 

Medical Disclaimer

 

This material is provided for general education and medical-travel planning. It is not a diagnosis, treatment recommendation, prognosis or substitute for consultation with a licensed clinician who has reviewed the complete medical record and examined the patient when required.

 

Re-biopsy, receptor testing, NGS, germline testing, systemic treatment and liver-directed procedures must be selected and interpreted by qualified medical professionals. Medicine approvals, indications, availability and funding differ between Türkiye and the patient’s home country and may change over time.

 

Do not stop, delay or change prescribed treatment on the basis of this article. Patients with severe symptoms, rapid deterioration or a possible emergency should seek immediate medical care where they are located rather than wait for international records review or travel.

 

Medical and Regulatory Sources